Literature DB >> 743489

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion.

B L Hillcoat, P B McCulloch, A T Figueredo, M H Ehsan, J M Rosenfeld.   

Abstract

Concentrations of 5-fluorouracil (FU) were measured in the plasma of patients receiving i.v. infusions of the drug for 5 days as treatment for adenocarcinoma of the gastrointestinal tract. Concentrations of FU varied widely in many patients. Concentration of drug X time of infusion (C X t values) were calculated. Patients showing a partial response or stabilization of disease had significantly higher C X t values than non-responders. Methyl CCNU did not affect the C X t values of FU. Determination of the plasma concentration of FU would allow the dose of the drug to be adjusted to maintain high concentrations of FU in the plasma. Our data suggest that such high concentrations would increase the response rate in this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 743489      PMCID: PMC2009832          DOI: 10.1038/bjc.1978.278

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  THE PHYSIOLOGIC DISPOSITION OF 5-FLUOROURACIL AND 5-FLUORO-2'-DEOXYURIDINE IN MAN.

Authors:  B CLARKSON; A O'CONNOR; L WINSTON; D HUTCHISON
Journal:  Clin Pharmacol Ther       Date:  1964 Sep-Oct       Impact factor: 6.875

Review 2.  Chemotherapy of colorectal carcinoma.

Authors:  P V Woolley; J S Macdonald; P S Schein
Journal:  Semin Oncol       Date:  1976-12       Impact factor: 4.929

3.  A sensitive assay of 5-fluorouracil in plasma by gas chromatography-mass spectrometry.

Authors:  B L Hillcoat; M Kawai; P B McCulloch; J Rosenfeld; C K Williams
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

4.  Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).

Authors:  J L Cohen; L E Irwin; G J Marshall; H Darvey; J R Bateman
Journal:  Cancer Chemother Rep       Date:  1974 Sep-Oct

5.  A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.

Authors:  R G Hahn; C G Moertel; A J Schutt; H W Bruckner
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

6.  Prediction of marrow toxicity in patients treated by intravenous infusion of 5 fluorouracil.

Authors:  B L Hillcoat; M Banerjee; P B McCulloch; C K Williams
Journal:  Eur J Cancer       Date:  1977-01       Impact factor: 9.162

7.  Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.

Authors:  P Seifert; L H Baker; M L Reed; V K Vaitkevicius
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

8.  Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine.

Authors:  C G Moertel; A J Schutt; R G Hahn; R J Reitemeier
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

  8 in total
  30 in total

Review 1.  'Toxgnostics': an unmet need in cancer medicine.

Authors:  David Church; Rachel Kerr; Enric Domingo; Dan Rosmarin; Claire Palles; Kevin Maskell; Ian Tomlinson; David Kerr
Journal:  Nat Rev Cancer       Date:  2014-05-15       Impact factor: 60.716

2.  Isolation-perfusion of the liver with 5-fluorouracil.

Authors:  W F Sindelar
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

Review 3.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.

Authors:  Maud Beneton; Sophie Chapet; Hélène Blasco; Bruno Giraudeau; Michèle Boisdron-Celle; Régine Deporte-Fety; Fabrice Denis; Bérangère Narcisso; Gilles Calais; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

6.  Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.

Authors:  G Milano; M Namer; J L Boublil; R Khater; M Frenay; A Thyss; J Bourry; C Philip; N Renée; J N Bruneton
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 7.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

8.  A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.

Authors:  Marie-Christine Etienne-Grimaldi; Eric François; Jean-Michel Cardot; Nicole Renée; Jean-Yves Douillard; Erick Gamelin; Jaafar Bennouna; Yann Château; Gérard Milano
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.

Authors:  Hei-Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Sung Hoon Noh; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Jpn J Clin Oncol       Date:  2009-10-31       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.